Shinonaga M, Hayashi J, Shinada S, Nakazawa S, Fujita Y, Ueno M, Equchi S
Second Department of Surgery, Niigata University School of Medicine.
Kyobu Geka. 1990 Apr;43(4):276-9.
We have used recombinant human erythropoietin (rEPO) in order to prevent patients from developing anemia following preoperative autologous blood preservation. Thereby, we have been able to reduce intraoperative homologous blood transfusion during cardiac operations. In June and July, 1989, six middle-aged selective patients received rEPO (200 IU/kg) intravenously every other day starting from fifteen days before the day of their operations. One unit (200 ml) of autologous blood was drawn and preserved every few days. However, no significant differences were observed in red cell counts, hematocrit, hemoglobin and serum protein levels between before and after preservation. Not only preoperative autologous blood preservation with provision of rEPO, but also using the intraoperative autotransfusion system enabled us to perform cardiac operations on 5 out of 6 patients without any homologous blood transfusion. None of the six patients exhibited any undesirable effects due to rEPO administration. Their postoperative courses were excellent.
我们使用重组人促红细胞生成素（rEPO）来预防患者在术前自体血保存后发生贫血。从而，我们得以减少心脏手术期间的术中异体输血。1989年6月和7月，6例择期手术的中年患者从手术日前15天开始每隔一天静脉注射rEPO（200 IU/kg）。每隔几天抽取并保存1单位（200 ml）自体血。然而，保存前后的红细胞计数、血细胞比容、血红蛋白和血清蛋白水平均未观察到显著差异。不仅术前自体血保存并给予rEPO，而且使用术中自体输血系统使我们能够对6例患者中的5例进行心脏手术而无需任何异体输血。6例患者中无一例因注射rEPO出现任何不良影响。他们的术后病程良好。
